

BromSite[®] (bromfenac) – First-time generic

- On February 13, 2024, [Lupin launched](#) an [AB-rated](#) generic version of Sun's [BromSite \(bromfenac\)](#) 0.075% ophthalmic solution.
 - In addition, Sun launched an authorized brand alternative of BromSite.
- BromSite is approved for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
- Bromfenac is also available generically as a [0.09% ophthalmic solution](#) and [0.07% ophthalmic solution](#).
 - Both these formulations carry similar indications as BromSite.
- According to IQVIA, BromSite had estimated annual sales in the U.S. of \$15 million as of December 2023.